Radiation Induced Oral Mucositis in Prostate Cancer - Epidemiology Forecast

List of Tables

Key Highlights:

Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide. Radiotherapy is a cornerstone of prostate cancer management, with an optimal utilization rate of about 60%. As a result, a substantial and growing survivorship population is exposed to pelvic irradiation.
The growing population of long-term prostate cancer survivors, driven by increased early-stage detection and expanded use of active surveillance, is sustaining and expanding the pool of patients at risk for radiation-induced toxicities, creating a persistent clinical need and potential market for supportive interventions.
Radiotherapy utilization is rising in both non-metastatic and metastatic settings, with advanced techniques like IMRT and SBRT becoming dominant, while conventional modalities decline; this trend toward higher precision and wider adoption indirectly increases the demand for managing late-onset mucositis and related pelvic radiation complications.
Across the 7MM, radiotherapy utilization and prostate cancer prevalence show notable variation: the US and UK report higher rates of radiotherapy use in localized disease (~42-49%) compared with Germany (~29%) and Japan (~16-17% for early-stage), while metastatic cases in the UK (~16%) are proportionally higher than in EU4 and Japan, reflecting country-specific screening practices, early detection rates, and clinical management approaches.

Radiation Induced Oral Mucositis in Prostate Cancer Infection Epidemiology forecast

2025 Radiation-Induced Mucositis in Prostate Cancer Among Radiotherapy Modalities: ~1,170,000
2036 Radiation-Induced Mucositis in Prostate Cancer Among Radiotherapy Modalities:

~ 1,416,000

Radiation Induced Oral Mucositis in Prostate Cancer Growth Rate (2026-2036): 1.6% CAGR

DelveInsight's 'Radiation Induced Oral Mucositis in Prostate Cancer - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Radiation Induced Oral Mucositis in Prostate Cancer , historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Radiation Induced Oral Mucositis in Prostate Cancer Understanding and Treatment Algorithm

Radiation Induced Oral Mucositis in Prostate Cancer Overview and Diagnosis

Radiation-induced toxicities form a spectrum of mucosal and organ injury after radiotherapy, especially in pelvic cancers. It often begins with mucositis, an inflammatory response of the oral and gastrointestinal mucosa that is painful but usually temporary. Pelvic radiation may progress to radiation proctitis, causing diarrhea, urgency, and bleeding acutely or chronic complications such as strictures and fistulas. Inflammation may also involve the bladder (radiation cystitis) with urinary symptoms, or the colon (radiation colitis), which can develop months to years after treatment and range from acute to chronic disease.

Risk factors for radiation-induced mucositis include radiation dose, treatment area, and delivery method. Doses below 45 Gy are linked to minimal long-term effects, while 45-70 Gy increases complications and doses above 70 Gy can cause severe, lasting tissue damage. Diagnosis involves blood and stool tests to detect infection or bleeding, endoscopic procedures such as flexible sigmoidoscopy or colonoscopy with biopsy to assess intestinal injury, as well as STI testing, urinalysis, and cystoscopy to evaluate urinary tract involvement.

Radiation Induced Oral Mucositis in Prostate Cancer Epidemiology

Key Findings from Radiation Induced Oral Mucositis in Prostate Cancer Epidemiological Analysis and Forecast

In 2025, the total cases of prevalent prostate cancer was 7,700,000 in the 7MM. These cases are expected to increase during the forecast period.
As per DelveInsight's estimates, In US, In prostate cancer the radiotherapy utilization is highest in localized disease, accounting for 270,000 cases in 2025 and projected to increase by 2036. This is followed by nmCSPC/nmHSPC, with 254,000 cases in 2025, expected to rise to by 2036.
IMRT is currently the most widely adopted and advanced form of radiotherapy in prostate cancer, accounting for the highest number of treated cases at 390,000 in 2025 and projected to increase by 2036.
This growth reflects its favorable toxicity profile and ability to deliver higher, more conformal doses. As IMRT continues to replace older techniques, its expanding use is expected to drive the overall radiotherapy-treated population and, consequently, the pool of patients at risk for radiation-related pelvic toxicities.

Scope of the Report:

The report covers a segment of a descriptive overview of Radiation Induced Oral Mucositis in Prostate Cancer , explaining their causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Radiation Induced Oral Mucositis in Prostate Cancer Patient population forecast

Report Key Strengths

Epidemiology-based (Epi-based) bottom-up forecasting
11-year forecast
Patient Burden trends (by geography)

FAQs:

What are the disease risks, burdens, and unmet needs of Radiation Induced Oral Mucositis in Prostate Cancer ? What will be the growth opportunities across the 7MM concerning the patient population with Radiation Induced Oral Mucositis in Prostate Cancer ?
What is the historical and forecasted Radiation Induced Oral Mucositis in Prostate Cancer patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Product Code: DIEI1829

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology and Market Forecast Methodology

5. Disease Background and Overview

5.1. Introduction
5.2. Radiation Therapy in Prostate Cancer
5.3. Radiotherapy Recommendation in prostate cancer
- 5.3.1. National Comprehensive Cancer Network Guidelines for Prostate Cancer (NCCN) (2024)
- 5.3.2. Japanese Urological Association: (2016)
  - 5.3.2.1. Prostate Cancer Treatment
- 5.3.3. National Institute for Health and Care Excellence (NICE) (2021)
- 5.3.4. SEOM Clinical Guidelines for mCSPC/mHNPC (2021)
- 5.3.5. European Association of Urology Guidelines for Prostate Cancer (2024)
5.4. Radiation induced Mucositis
- 5.4.1. Etiology
- 5.4.2. Risk Factors
- 5.4.3. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings
6.2. Assumptions and Rationale
6.3. The 7MM
- 6.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM
- 6.3.2. Five-year Prevalent Cases of Prostate Cancer in the 7MM
- 6.3.3. Total Prevalent Cases of Prostate Cancer by Clinical Stages in the 7MM
  - 6.3.3.1. Total Prevalent Cases of nmCSPC in the 7MM
  - 6.3.3.2. Total Prevalent Cases of mCSPC in the 7MM
  - 6.3.3.3. Total Prevalent Cases of nmCRPC in the 7MM
  - 6.3.3.4. Total Prevalent Cases of mCRPC in the 7MM
- 6.3.4. Total Radiation-Induced Mucositis in Prostate Cancer among Radiotherapy Modalities in the 7MM
6.4. The United States
- 6.4.1. Radiotherapy Utilization in Prostate Cancer in the US
- 6.4.2. Radiotherapy Modalities in Prostate Cancer in the US
- 6.4.3. Radiation-Induced Mucositis in Prostate Cancer among Radiotherapy Modalities in the US
  - 6.4.3.1. Radiation-Induced Proctitis in Prostate Cancer in the US
  - 6.4.3.2. Radiation-Induced Cystitis in Prostate Cancer in the US
  - 6.4.3.3. Radiation-Induced Colitis in Prostate Cancer in the US
6.5. EU4 and the UK
- 6.5.1. Radiotherapy Utilization in Prostate Cancer in the EU4 and the UK
- 6.5.2. Radiotherapy Modalities in Prostate Cancer in EU4 and the UK
- 6.5.3. Radiation-Induced Mucositis in Prostate Cancer among Radiotherapy Modalities in EU4 and the UK
  - 6.5.3.1. Radiation-Induced Proctitis in Prostate Cancer in EU4 and the UK
  - 6.5.3.2. Radiation-Induced Cystitis in Prostate Cancer in EU4 and the UK
  - 6.5.3.3. Radiation-Induced Colitis in Prostate Cancer in the EU4 and the UK
6.6. Japan
- 6.6.1. Radiotherapy Utilization in Prostate Cancer in Japan
- 6.6.2. Radiotherapy Modalities in Prostate Cancer in the Japan
- 6.6.3. Radiation-Induced Mucositis in Prostate Cancer among Radiotherapy Modalities in Japan
  - 6.6.3.1. Radiation-Induced Proctitis in Prostate Cancer in Japan
  - 6.6.3.2. Radiation-Induced Cystitis in Prostate Cancer in Japan
  - 6.6.3.3. Radiation-Induced Colitis in Prostate Cancer in Japan

7. Appendix

7.1. Bibliography
7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

Product Code: DIEI1829

List of Tables

Table 1: Summary of Radiation-induced mucositis in Prostate Cancer Epidemiology (2026-2036)
Table 2: Prostate Cancer Staging and Grading (TNM & Gleason)
Table 3: Grades of Recommendation Used in Japanese Urological Association Guideline
Table 4: Radiotherapy (external irradiation)
Table 5: Radiotherapy (interstitial irradiation)
Table 6: Prevalence of Prostate Cancer in the 7MM
Table 7: Total Prevalent Cases of Prostate Cancer in the 7MM in Thousands (2022-2036)
Table 8: Five-year Prevalent Cases of Prostate Cancer in the 7MM in Thousands (2022-2036)
Table 9: Total Prevalent Cases of nmCSPC in the 7MM (2022-2036)
Table 10: Total Prevalent Cases of mCSPC in the 7MM (2022-2036)
Table 11: Total Prevalent Cases of nmCRPC in the 7MM (2022-2036)
Table 12: Total Prevalent Cases of mCRPC in the 7MM (2022-2036)
Table 13: Total Radiation-Induced Mucositis in Prostate Cancer among Radiotherapy Modalities in the 7MM in Thousands (2022-2036)
Table 14: Radiotherapy Utilization in Prostate Cancer in the US (2022-2036)
Table 15: Radiotherapy Modalities in Prostate Cancer in the US (2022-2036)
Table 16: Radiation-Induced Proctitis in Prostate Cancer in the US (2022-2036)
Table 17: Radiation-Induced Cystitis in Prostate Cancer in the US (2022-2036)
Table 18: Radiation-Induced Colitis in Prostate Cancer in the US (2022-2036)
Table 19: Radiotherapy Utilization in Prostate Cancer in Germany (2022-2036)
Table 20: Radiotherapy Utilization in Prostate Cancer in France (2022-2036)
Table 21: Radiotherapy Utilization in Prostate Cancer in Italy (2022-2036)
Table 22: Radiotherapy Utilization in Prostate Cancer in Spain (2022-2036)
Table 23: Radiotherapy Utilization in Prostate Cancer in the UK (2022-2036)
Table 24: Radiotherapy Utilization in Prostate Cancer in EU4 and the UK (2022-2036)
Table 25: Types of Radiotherapy Modalities Used in Prostate Cancer in Germany (2022-2036)
Table 26: Types of Radiotherapy Modalities Used in Prostate Cancer in France (2022-2036)
Table 27: Types of Radiotherapy Modalities Used in Prostate Cancer in Italy (2022-2036)
Table 28: Types of Radiotherapy Modalities Used in Prostate Cancer in Spain (2022-2036)
Table 29: Types of Radiotherapy Modalities Used in Prostate Cancer in the UK (2022-2036)
Table 30: Types of Radiotherapy Modalities Used in Prostate Cancer in EU4 and the UK (2022-2036)
Table 31: Radiation-Induced Proctitis in Prostate Cancer in Germany (2022-2036)
Table 32: Radiation-Induced Proctitis in Prostate Cancer in France (2022-2036)
Table 33: Radiation-Induced Proctitis in Prostate Cancer in Italy (2022-2036)
Table 34: Radiation-Induced Proctitis in Prostate Cancer in Spain (2022-2036)
Table 35: Radiation-Induced Proctitis in Prostate Cancer in the UK (2022-2036)
Table 36: Radiation-Induced Proctitis in Prostate Cancer in EU4 and the UK (2022-2036)
Table 37: Radiation-Induced Proctitis in Prostate Cancer in EU4 and the UK (2022-2036)
Table 38: Radiation-Induced Cystitis in Prostate Cancer in Germany (2022-2036)
Table 39: Radiation-Induced Cystitis in Prostate Cancer in France (2022-2036)
Table 40: Radiation-Induced Cystitis in Prostate Cancer in Italy (2022-2036)
Table 41: Radiation-Induced Cystitis in Prostate Cancer in Spain (2022-2036)
Table 42: Radiation-Induced Cystitis in Prostate Cancer in the UK (2022-2036)
Table 43: Radiation-Induced Cystitis in Prostate Cancer in EU4 and the UK (2022-2036)
Table 44: Radiation-Induced Colitis in Prostate Cancer in Germany (2022-2036)
Table 45: Radiation-Induced Colitis in Prostate Cancer in France (2022-2036)
Table 46: Radiation-Induced Colitis in Prostate Cancer in Italy (2022-2036)
Table 47: Radiation-Induced Colitis in Prostate Cancer in Spain (2022-2036)
Table 48: Radiation-Induced Colitis in Prostate Cancer in the UK (2022-2036)
Table 49: Radiation-Induced Colitis in Prostate Cancer in EU4 the UK (2022-2036)
Table 50: Radiotherapy Utilization in Prostate Cancer in Japan (2022-2036)
Table 51: Radiotherapy Modalities in Prostate Cancer in Germany (2022-2036)
Table 52: Radiation-Induced Proctitis in Prostate Cancer in Japan (2022-2036)
Table 53: Radiation-Induced Cystitis in Prostate Cancer in Japan (2022-2036)
Table 54: Radiation-Induced Colitis in Prostate Cancer in Japan (2022-2036)

List of Figures

Figure 1: High or Very High-risk Group
Figure 2: Regional Risk Group (Any T, N1, M0)
Figure 3: Monitoring of PSA Persistence/Recurrence
Figure 4: Sigmoidoscopy
Figure 5: Colonoscopy
Figure 6: Rectal Spacers
Figure 7: Global Heat Map of Prostate Cancer
Figure 8: Total Prevalent Cases of Prostate Cancer in the 7MM (2022-2036)
Figure 9: Five-year Prevalent Cases of Prostate Cancer in the 7MM (2022-2036)
Figure 10: Total Prevalent Cases of nmCSPC in the 7MM (2022-2036)
Figure 11: Total Prevalent Cases of mCSPC in the 7MM (2022-2036)
Figure 12: Total Prevalent Cases of nmCRPC in the 7MM (2022-2036)
Figure 13: Total Prevalent Cases of mCRPC in the 7MM (2022-2036)
Figure 14: Total Radiation-Induced Mucositis in Prostate Cancer among Radiotherapy Modalities in the 7MM (2022-2036)
Figure 15: Radiotherapy Utilization in Prostate Cancer in the US (2022-2036)
Figure 16: Radiotherapy Modalities in Prostate Cancer in the US (2022-2036)
Figure 17: Radiation-Induced Proctitis in Prostate Cancer in the US (2022-2036)
Figure 18: Radiation-Induced Cystitis in Prostate Cancer in the US (2022-2036)
Figure 19: Radiation-Induced Colitis in Prostate Cancer in the US (2022-2036)
Figure 20: Radiotherapy Utilization in Prostate Cancer in the EU4 and the UK (2022-2036)
Figure 21: Types of Radiotherapy Used in Prostate Cancer in EU4 and the UK (2022-2036)
Figure 22: Radiation-Induced Proctitis in Prostate Cancer in EU4 and the UK (2022-2036)
Figure 23: Radiation-Induced Cystitis in Prostate Cancer in EU4 and the UK (2022-2036)
Figure 24: Radiation-Induced Colitis in Prostate Cancer in the EU4 and the UK (2022-2036)
Figure 25: Radiotherapy Utilization in Prostate Cancer in Japan (2022-2036)
Figure 26: Radiotherapy Modalities in Prostate Cancer in the US (2022-2036)
Figure 27: Radiation-Induced Proctitis in Prostate Cancer in Japan (2022-2036)
Figure 28: Radiation-Induced Cystitis in Prostate Cancer in Japan (2022-2036)
Figure 29: Radiation-Induced Colitis in Prostate Cancer in Japan (2022-2036)

Radiation Induced Oral Mucositis in Prostate Cancer - Epidemiology Forecast - 2036

Description

Table of Contents

List of Tables

Key Highlights:

Radiation Induced Oral Mucositis in Prostate Cancer Understanding and Treatment Algorithm

Radiation Induced Oral Mucositis in Prostate Cancer Epidemiology

Scope of the Report:

Report Insights

Report Key Strengths

FAQs:

Reasons to Buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology and Market Forecast Methodology

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Appendix

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables

List of Figures